search
Back to results

Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
MK-4618
Placebo for MK-4618
Metoprolol
Amlodipine
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female not of childbearing potential
  • Not a nursing mother
  • Must be on stable dose of a beta blocker (Panel A only) or amlodipine (Panel B only) for the treatment of hypertension for at least 6 weeks prior to enrollment. Must take the designated daily dose of metoprolol or amlodipine for the duration of the study
  • In good health other than hypertension
  • Nonsmoker
  • Participant has a resting systolic blood pressure <150 and >95 mmHg and a diastolic blood pressure <95 and >75 mmHg at prestudy clinical evaluation

Exclusion Criteria:

  • Any illness that might confound the results of the study or pose a risk by participation
  • History of orthostatic hypotension (decrease in blood pressure upon standing accompanied by symptoms of lightheadedness or dizziness)
  • History of cancer, excepting certain skin or cervical cancers or cancers that were treated successfully 10 or more years prior to screening
  • Condition for which there is a warning, contraindication, or precaution against the use of extended release metoprolol (Panel A) or amlodipine (Panel B)
  • Consumes excessive amounts of alcohol or caffeine daily
  • Has multiple and/or severe allergies (including latex allergy) or has had an anaphylactic reaction or significant intolerance to drugs or food
  • Uses illicit drugs or has a history of drug abuse

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Arm Label

    Panel A: MK-4618 + Met → PBO + Met

    Panel A: PBO + Met → MK-4618 + Met

    Panel B: MK-4618 + Amlo → PBO + Amlo

    Panel B: PBO + Amlo → MK-4618 + Amlo

    Arm Description

    Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.

    Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.

    Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.

    Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.

    Outcomes

    Primary Outcome Measures

    Percentage of Participants With a Clinical or Laboratory Adverse Experience
    An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product is also an adverse experience. The percentage of participants with a clinical or laboratory adverse experience was recorded.
    Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel A
    Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.
    Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel B
    Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.

    Secondary Outcome Measures

    Steady-state Area Under the Plasma Concentration Versus Time Curve (AUC0-24hr) for MK-4618
    Blood samples were collected on Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose for the determination of plasma MK-4618 concentration. The hypothesis for this outcome is that the steady-state AUC0-24hr for MK-4618 is >=0.47 uM*hr.

    Full Information

    First Posted
    April 15, 2011
    Last Updated
    December 3, 2018
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01337674
    Brief Title
    Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)
    Official Title
    A Study to Evaluate the Co-Administration of MK-4618 With Antihypertensive Agents
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    April 1, 2011 (Actual)
    Primary Completion Date
    November 1, 2011 (Actual)
    Study Completion Date
    November 1, 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study will evaluate the safety and tolerability of MK-4618 when coadministered with antihypertensive agents and will evaluate changes in blood pressure following co-administration of MK-4618 with a beta blocker and a vasodilator. The primary hypothesis of the study is that MK-4618 does not result in a clinically meaningful change in systolic blood pressure relative to placebo when co-administered with a beta-blocker or with amlodipine.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    26 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Panel A: MK-4618 + Met → PBO + Met
    Arm Type
    Experimental
    Arm Description
    Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
    Arm Title
    Panel A: PBO + Met → MK-4618 + Met
    Arm Type
    Experimental
    Arm Description
    Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
    Arm Title
    Panel B: MK-4618 + Amlo → PBO + Amlo
    Arm Type
    Experimental
    Arm Description
    Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
    Arm Title
    Panel B: PBO + Amlo → MK-4618 + Amlo
    Arm Type
    Experimental
    Arm Description
    Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
    Intervention Type
    Drug
    Intervention Name(s)
    MK-4618
    Intervention Description
    Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo for MK-4618
    Intervention Description
    Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
    Intervention Type
    Drug
    Intervention Name(s)
    Metoprolol
    Other Intervention Name(s)
    Toprol-XL
    Intervention Description
    Previously prescribed daily dose of open-label metoprolol for the duration of the study
    Intervention Type
    Drug
    Intervention Name(s)
    Amlodipine
    Other Intervention Name(s)
    Norvasc
    Intervention Description
    Previously prescribed daily dose of open-label amlodipine for the duration of the study
    Primary Outcome Measure Information:
    Title
    Percentage of Participants With a Clinical or Laboratory Adverse Experience
    Description
    An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product is also an adverse experience. The percentage of participants with a clinical or laboratory adverse experience was recorded.
    Time Frame
    Up to 42 days
    Title
    Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel A
    Description
    Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.
    Time Frame
    Baseline (predose) and up to 24 hours postdose on Day 1 and Day 7
    Title
    Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel B
    Description
    Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.
    Time Frame
    Baseline (predose) and up to 24 hours postdose on Day 1 and Day 7
    Secondary Outcome Measure Information:
    Title
    Steady-state Area Under the Plasma Concentration Versus Time Curve (AUC0-24hr) for MK-4618
    Description
    Blood samples were collected on Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose for the determination of plasma MK-4618 concentration. The hypothesis for this outcome is that the steady-state AUC0-24hr for MK-4618 is >=0.47 uM*hr.
    Time Frame
    Predose and up to 24 hours postdose on Day 7

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female not of childbearing potential Not a nursing mother Must be on stable dose of a beta blocker (Panel A only) or amlodipine (Panel B only) for the treatment of hypertension for at least 6 weeks prior to enrollment. Must take the designated daily dose of metoprolol or amlodipine for the duration of the study In good health other than hypertension Nonsmoker Participant has a resting systolic blood pressure <150 and >95 mmHg and a diastolic blood pressure <95 and >75 mmHg at prestudy clinical evaluation Exclusion Criteria: Any illness that might confound the results of the study or pose a risk by participation History of orthostatic hypotension (decrease in blood pressure upon standing accompanied by symptoms of lightheadedness or dizziness) History of cancer, excepting certain skin or cervical cancers or cancers that were treated successfully 10 or more years prior to screening Condition for which there is a warning, contraindication, or precaution against the use of extended release metoprolol (Panel A) or amlodipine (Panel B) Consumes excessive amounts of alcohol or caffeine daily Has multiple and/or severe allergies (including latex allergy) or has had an anaphylactic reaction or significant intolerance to drugs or food Uses illicit drugs or has a history of drug abuse
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Director
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
    IPD Sharing URL
    http://engagezone.msd.com/ds_documentation.php
    Available IPD and Supporting Information:
    Available IPD/Information Type
    CSR Synopsis
    Available IPD/Information URL
    http://www.merck.com/clinical-trials/study.html?id=4618-010&kw=4618-010&tab=access

    Learn more about this trial

    Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)

    We'll reach out to this number within 24 hrs